The Gastrointestinal Cancer Channel is supported with funding from Gilead Sciences (Silver) and Revolution Medicines (Silver).
VJOncology is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
ASCO GI 2021 | ARROW: clinical activity of pralsetinib in RET-fusion positive solid tumors
Vivek Subbiah, MD, The University of Texas MD Anderson Cancer Center, Houston, TX, discusses the clinical activity of the potent and selective RET inhibitor pralsetinib in patients with RET fusion-positive solid tumors. Pralsetinib is currently approved for use in non-small cell lung cancer, however, due to the prevalence of RET fusions in gastrointestinal malignancies, RET inhibition may prove an effective treatment pathway for this patient population. Dr Subbiah highlights the clinical activity of pralsetinib in non-NSCLC cancer patients enrolled in the Phase I/II ARROW study (NCT03037385). This interview was recorded via an online conference call with The Video Journal of Oncology (VJOncology).
